67
Participants
Start Date
February 16, 2020
Primary Completion Date
October 31, 2023
Study Completion Date
October 31, 2023
PARP Inhibitor BGB-290
Given PO
Temozolomide
Given PO
Therapeutic Conventional Surgery
resection surgery
Hillman Cancer Center at University of Pittsburgh Cancer Institute, Pittsburgh
University of Pennsylvania, Philadelphia
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore
University of Virginia, Charlottesville
Cleveland Clinic Taussig Cancer Center, Cleveland
Josephine Ford Cancer Center at Henry Ford Hospital, Detroit
Washington University, St Louis
University of California, Los Angeles, Los Angeles
UAB Comprehensive Cancer Center, Birmingham
Yale University, New Haven
Dana Farber Cancer Institute, Boston
Wake Forest University Comprehensive Cancer Center, Winston-Salem
Collaborators (1)
National Cancer Institute (NCI)
NIH
BeiGene
INDUSTRY
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
OTHER